Hormonal Treatment

Xtandi for prostate cancer before Taxotere

Enzalutamide (Xtandi, MDV3100) is an androgen receptor antagonist drug that produces an up to an 89% decrease in prostate specific antigen serum levels after a month of use. It is more potent than Casodex. In August of 2012, the U.S. Food and Drug Administration approved enzalutamide for the treatment of castration-resistant prostate cancer in patients who failed docetaxel. This was based on the AFFIRM study results. AFFIRM showed that Enzalutamide

Read more
MDV3100 for prostate cancer

  MDV3100 is an androgen receptor antagonist drug developed with promise for hormone refractory prostate cancer, and it is in Phase 3 clinical trials and for breast cancer. MDV3100 has binds five times stronger to the androgen receptor (AR) than Casodex, a popular hormonal drug that is currently used. It also interacts with the cancer cels in other ways. Median time to radiographic progression in a phase II study was 56 weeks for chemo-naive

Read more